Ultragenyx Pharmaceutical Inc. (NASDAQ:RARE – Get Free Report) CAO Theodore Huizenga sold 1,283 shares of the stock in a transaction on Tuesday, September 15th. The shares were sold at an average price of $13.57, for a total value of $17,410.31. Following the sale, the chief accounting officer directly owned 67,863 shares in the company, valued at approximately $920,900.91. The trade was a 1.86% decrease in their position. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through the SEC website.
Theodore Alan Huizenga also recently made the following trade(s):
- On Thursday, September 3rd, Theodore Huizenga sold 161 shares of Ultragenyx Pharmaceutical stock. The shares were sold at an average price of $13.99, for a total transaction of $2,252.39.
Ultragenyx Pharmaceutical Price Performance
NASDAQ:RARE traded down $0.54 on Tuesday, reaching $13.07. The stock had a trading volume of 5,641,382 shares, compared to its average volume of 2,527,528. Ultragenyx Pharmaceutical Inc. has a 12-month low of $12.88 and a 12-month high of $39.89. The company has a market cap of $1.29 billion, a price-to-earnings ratio of -2.24 and a beta of 0.31. The firm’s fifty day moving average is $25.56 and its two-hundred day moving average is $24.70.
Analysts Set New Price Targets
A number of research analysts have weighed in on the company. Bank of America lowered Ultragenyx Pharmaceutical from a “buy” rating to a “neutral” rating in a research note on Thursday, September 3rd. Wells Fargo & Company lowered Ultragenyx Pharmaceutical from an “overweight” rating to an “equal weight” rating and dropped their target price for the company from $50.00 to $18.00 in a research note on Thursday, September 3rd. Citigroup reduced their target price on Ultragenyx Pharmaceutical from $58.00 to $28.00 and set a “buy” rating on the stock in a research report on Thursday, September 3rd. Jefferies Financial Group decreased their price target on Ultragenyx Pharmaceutical from $77.00 to $28.00 and set a “buy” rating on the stock in a research note on Thursday, September 3rd. Finally, Wedbush lowered their price target on Ultragenyx Pharmaceutical from $30.00 to $23.00 and set a “neutral” rating for the company in a report on Thursday, September 3rd. One investment analyst has rated the stock with a Strong Buy rating, ten have issued a Buy rating, nine have given a Hold rating and one has given a Sell rating to the stock. Based on data from MarketBeat, the stock has an average rating of “Moderate Buy” and a consensus price target of $36.63.
Read Our Latest Report on RARE
Institutional Trading of Ultragenyx Pharmaceutical
Institutional investors and hedge funds have recently made changes to their positions in the company. Parallel Advisors LLC boosted its holdings in Ultragenyx Pharmaceutical by 778.4% in the first quarter. Parallel Advisors LLC now owns 1,625 shares of the biopharmaceutical company’s stock valued at $34,000 after acquiring an additional 1,440 shares during the last quarter. Leonteq Securities AG increased its stake in Ultragenyx Pharmaceutical by 288.5% during the first quarter. Leonteq Securities AG now owns 1,795 shares of the biopharmaceutical company’s stock worth $38,000 after acquiring an additional 1,333 shares during the last quarter. Versant Capital Management Inc increased its stake in Ultragenyx Pharmaceutical by 662.9% during the second quarter. Versant Capital Management Inc now owns 1,152 shares of the biopharmaceutical company’s stock worth $38,000 after acquiring an additional 1,001 shares during the last quarter. EverSource Wealth Advisors LLC raised its holdings in shares of Ultragenyx Pharmaceutical by 573.0% in the 1st quarter. EverSource Wealth Advisors LLC now owns 2,167 shares of the biopharmaceutical company’s stock worth $45,000 after purchasing an additional 1,845 shares during the period. Finally, Quantbot Technologies LP purchased a new position in shares of Ultragenyx Pharmaceutical in the 2nd quarter worth about $48,000. 97.67% of the stock is currently owned by institutional investors and hedge funds.
About Ultragenyx Pharmaceutical
Ultragenyx Pharmaceutical Inc is a biopharmaceutical company focused on developing and commercializing treatments for rare and ultra-rare diseases. The company’s work includes therapies for genetic, metabolic and skeletal disorders, with an emphasis on conditions that have limited or no effective treatment options.
Ultragenyx’s marketed products include Crysvita (burosumab), used to treat certain forms of X-linked hypophosphatemia and tumor-induced osteomalacia; Dojolvi (triheptanoin), a medical food for long-chain fatty acid oxidation disorders; and Evkeeza (evinacumab), a treatment for homozygous familial hypercholesterolemia.
See Also
- Five stocks we like better than Ultragenyx Pharmaceutical
- Running on Empty: 3 Energy Plays for Europe’s Deep Freeze
- 3 Healthcare Stocks for 3 Stages of Life
- Curaleaf Tries To Roll Up Aurora In a Hostile Cannabis Bid
- MarketBeat’s Most Downgraded Stocks in Q3: 2 Look Cheap, 1 Looks Risky
Receive News & Ratings for Ultragenyx Pharmaceutical Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Ultragenyx Pharmaceutical and related companies with MarketBeat.com's FREE daily email newsletter.
